We conclude that a potential therapeutic approach aimed at increasing the NAD+ level by using vitamin precursors or inhibiting PARP activity could be useful for the treatment of several mitochondrial dysfunction-associated forms of PD. Here, PARP1 is linked to Parkinson disease.